1
|
Abstract
Waldenström macroglobulinemia (WM) is a rare subtype of non-Hodgkin lymphoma characterized by the presence of lymphoplasmacytic lymphoma (LPL) in the bone marrow accompanied by a monoclonal immunoglobulin type M (IgM) in the serum. WM was first described only 80 years ago and became reportable in the US as a malignancy in 1988. Very little systematic research was conducted prior to 2000 to characterize incidence, clinical characteristics, risk factors or diagnostic and prognostic criteria, and there were essentially no WM-specific clinical interventional trials. Since the inaugural meeting of the International Workshop in Waldenström's Macroglobulinemia (IWWM) in 2000, WM has become the focus of a steadily increasing and productive body of research, engaging a growing number of investigators throughout the world. This introductory overview provides summary of the current understanding of the epidemiology of WM/LPL as a backdrop for a series of consensus panel recommendations arising from research presented at the 11th IWWM.
Collapse
Affiliation(s)
- Mary L McMaster
- Division of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, National Institutes of Health, Bethesda, MD; Department of Health and Human Services, Commissioned Corps of the United States Public Health Service, Washington, DC.
| |
Collapse
|
2
|
Sudden and unexpected death due to intracranial sellar extramedullary plasmacytoma. J Forensic Leg Med 2018; 61:89-91. [PMID: 30503990 DOI: 10.1016/j.jflm.2018.11.012] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2018] [Revised: 10/03/2018] [Accepted: 11/22/2018] [Indexed: 11/21/2022]
Abstract
The incidence of sudden death caused by undiagnosed primary intracranial neoplasm in young adults is extremely low. The aim of the work is to present a case report of the sudden death of a 24-year-old woman. The autopsy has revealed enlargement of sella turcica with an intrasellar tumorous mass extending into the adjacent basal parts of the brain. A tumour was diagnosed as an extramedullary plasmacytoma. The cause of death was established as a failure of the central nervous system. Toxicological analyses of biological materials were negative. According to the case history, a woman reportedly had no serious health problems. Finding of an extensive intracranial tumour in the sella turcica was random and surprising. The presented case is an extremely rare case of sudden death caused by intracranial intrasellar extramedullary plasmacytoma without previous clinical manifestation.
Collapse
|
3
|
Minnicelli C, Maciel JFR, Hassan R, Lemos TMAM. Clinical and epidemiological features of multiple myeloma patients from a low socio-economic region of Brazil. Rev Bras Hematol Hemoter 2015; 37:354-5. [PMID: 26408372 PMCID: PMC4685045 DOI: 10.1016/j.bjhh.2015.05.007] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2015] [Revised: 05/01/2015] [Accepted: 05/08/2015] [Indexed: 11/19/2022] Open
Affiliation(s)
| | | | - Rocio Hassan
- Instituto Nacional do Câncer (INCA), Rio de Janeiro, RJ, Brazil
| | | |
Collapse
|
4
|
Hematological malignancies in Al-amal oncology unit, aden. Indian J Hematol Blood Transfus 2013; 28:19-23. [PMID: 23449749 DOI: 10.1007/s12288-011-0101-3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2010] [Accepted: 07/27/2011] [Indexed: 01/02/2023] Open
Abstract
The hematological malignancies (HM) are group of neoplasms that arise through malignant transformation of bone marrow derived cells. The great diversity seen in this group of disorders is a reflection of the complexity of normal hematopoiesis and the immune system. In the current study, the author retrospectively studied HM patients from 2008 to 2010, and compared with prevalence of solid tumor, and found HM represented one-fifth of all malignancies managed in the Oncology Unit, and lymphomas were the commonest HM.
Collapse
|
5
|
Jimenez-Zepeda VH, Neme-Yunes Y, Braggio E. Chromosome abnormalities defined by conventional cytogenetics in plasma cell leukemia: what have we learned about its biology? Eur J Haematol 2011; 87:20-7. [PMID: 21692850 DOI: 10.1111/j.1600-0609.2011.01629.x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Cancer cells are characterized by having chromosomal abnormalities. The number of aberrations and the specific chromosomes affected are likely correlated with tumor progression. In this study, we analyzed the karyotype of 126 plasma cell leukemia (PCL) patients to identify the most frequently occurring imbalances and to design a model of karyotypic evolution. The Mitelman database of chromosome was searched and abnormal karyotypes were assessed. The main clones were analyzed and chromosomal gains and losses were used to design a model of genetic acquisition based on the calculation of a variable called time to occurrence. Our comprehensive study of genetic abnormalities of a large number of PCL karyotypes suggests that PCL is mainly characterized by the presence of whole chromosome losses as well as IgH rearrangements which is similar to that observed in non-hyperdiploid multiple myeloma (MM). Temporal analysis suggests that most PCL have around 10 abnormalities at diagnosis. It is possible that accumulation of abnormalities such as 17p13 (TP53) and 1p losses may trigger the extramedullary features of PCL. Our study demonstrates that cytogenetics is a valuable tool to evaluate the role of genetic imbalances on karyotypic evolution by using a mathematical model.
Collapse
|
6
|
Turk HM, Komurcu S, Ozet A, Kuzhan O, Günhan O. An unusual presentation of extramedullary plasmacytoma in testis and review of the literature. Med Oncol 2009; 27:1378-80. [PMID: 20035386 DOI: 10.1007/s12032-009-9390-x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2009] [Accepted: 12/09/2009] [Indexed: 11/24/2022]
Abstract
Extramedullary plasmacytoma is a rare plasma cell neoplasm, and it is extremely uncommon in the testicles. We report a 73-year-old man with multiple myeloma presented with testicular plasmacytoma. He complained of left leg pain and scrotal swelling. Ultrasonography revealed testicular masses. Pathologic examination of the orchiectomy specimen showed plasmocytoma with kappa expression. Multiple lytic bone lesions were seen in bone survey scans, serum immunoelectrophoresis and bone marrow aspiration aided to the diagnosis of multiple myeloma. He received chemotherapy, melphalan and prednisolone, and palliative radiotherapy. He succumbed to disease after 8 months.
Collapse
Affiliation(s)
- H Mehmet Turk
- Department of Clinical Oncology, Faculty of Medicine, Gaziantep University, Gaziantep, 27310, Turkey.
| | | | | | | | | |
Collapse
|
7
|
Kyle RA, Jacobus S, Friedenberg WR, Slabber CF, Rajkumar SV, Greipp PR. The treatment of multiple myeloma using vincristine, carmustine, melphalan, cyclophosphamide, and prednisone (VBMCP) alternating with high-dose cyclophosphamide and alpha(2)beta interferon versus VBMCP: results of a phase III Eastern Cooperative Oncology Group Study E5A93. Cancer 2009; 115:2155-64. [PMID: 19248045 DOI: 10.1002/cncr.24221] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
BACKGROUND A randomized controlled trial tested the hypothesis that aggressive initial therapy using high-dose cyclophosphamide (HiCy) and alpha(2)beta interferon (IFN) may be superior to standard combination alkylating agent regimens in the treatment of newly diagnosed myeloma. METHODS This Eastern Cooperative Oncology Group trial evaluated 268 previously untreated patients with active multiple myeloma randomized to vincristine, carmustine, melphalan, cyclophosphamide, and prednisone (VBMCP) or VBMCP plus HiCy and recombinant IFN. RESULTS The overall objective response was 62% in the VBMCP regimen and 68% in the VBMCP + HiCy + IFN group. The near complete response and complete response rates were 8.1% and 8.9%, respectively. Progression-free survival was 22.1 and 25.3 months, respectively. The median overall survival was 37.1 months for patients treated with VBMCP and 41.3 months for those treated with VBMCP + HiCy + IFN (P = .38). The 5-year overall survival rates were not significantly different between the 2 arms: 26.4% and 33%, respectively. Lethal toxicities occurred in 15 patients, including 10 from infection, but there was no significant difference in lethal toxicities between the 2 regimens. CONCLUSIONS The study showed no significant benefit with the addition of HiCy and IFN to VBMCP.
Collapse
Affiliation(s)
- Robert A Kyle
- Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
| | | | | | | | | | | |
Collapse
|
8
|
Loh YS, Mo S, Brown RD, Yamagishi T, Yang S, Joshua DE, Roufogalis BD, Sze DMY. Presence of Hoechst low side populations in multiple myeloma. Leuk Lymphoma 2008; 49:1813-6. [PMID: 18798111 DOI: 10.1080/10428190802272676] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
|
9
|
Eurelings M, Lokhorst HM, Kalmijn S, Wokke JHJ, Notermans NC. Malignant transformation in polyneuropathy associated with monoclonal gammopathy. Neurology 2005; 64:2079-84. [PMID: 15985576 DOI: 10.1212/01.wnl.0000176296.79088.9a] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Objective: To assess the frequency of hematologic malignancies at diagnosis and to determine the incidence and predictors of malignant transformation during follow-up in patients with polyneuropathy associated with monoclonal gammopathy.Methods: Potential predictors of malignant transformation from medical history, hematologic, neurologic, and laboratory examination performed each 6 months were evaluated by univariable and multivariable Cox proportional hazard analysis.Results: Of 193 patients with polyneuropathy associated with monoclonal gammopathy, 17 patients had a hematologic malignancy at diagnosis. The incidence rate of malignant transformation in 176 patients without a malignancy at diagnosis was 2.7/100 patient years. Weight loss, progression of the polyneuropathy, unexplained fever or night sweats, and M-protein level were independent predictors.Conclusions: Since hematologic malignancies occur frequently in polyneuropathy associated with monoclonal gammopathy, the authors suggest that all patients should be screened at diagnosis and subsequently during follow-up if malignant transformation is suspected.
Collapse
Affiliation(s)
- M Eurelings
- Department of Neurology, Rudolf Magnus Institute of Neuroscience, Utrecht, The Netherlands.
| | | | | | | | | |
Collapse
|
10
|
Pusterla N, Stacy BA, Vernau W, De Cock HEV, Magdesian KG. Immunoglobulin A monoclonal gammopathy in two horses with multiple myeloma. Vet Rec 2004; 155:19-23. [PMID: 15264485 DOI: 10.1136/vr.155.1.19] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
The clinical findings in two horses with secretory multiple myeloma and secondary immunoglobulin A (IgA) monoclonal gammopathy were non-specific and included weight loss, pale mucous membranes, limb oedema and bacterial respiratory tract infection. Consistent laboratory abnormalities included hyperproteinaemia, hyperglobulinaemia, hypoalbuminaemia and hypercalcaemia. The diagnosis was based on the presence of IgA monoclonal gammopathy in serum and urine and bone marrow plasmacytosis (> 10 per cent). One horse was euthanased; it had neoplastic plasma cell infiltrates in its kidneys, spleen, liver, bone marrow, myocardium and adrenal glands. The other horse was treated for a bacterial pneumonia and was still alive six months after it was first examined.
Collapse
Affiliation(s)
- N Pusterla
- Department of Medicine and Epidemiology, School of Veterinary Medicine, University of California, Davis, CA 95616, USA
| | | | | | | | | |
Collapse
|
11
|
Peterson LC, Agosti SJ, Hoyer JD. Protocol for the examination of specimens from patients with hematopoietic neoplasms of the bone marrow: a basis for checklists. Arch Pathol Lab Med 2002; 126:1050-6. [PMID: 12240626 DOI: 10.5858/2002-126-1050-pfteos] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- LoAnn C Peterson
- Department of Pathology, Hematopathology, Northwestern University Medical School, Chicago, Ill 60611, USA.
| | | | | |
Collapse
|
12
|
Dyagil I, Adam M, Beebe GW, Burch JD, Gaidukova SN, Gluzman D, Gudzenko N, Klimenko V, Peterson L, Reiss RF, Finch SC. Histologic verification of leukemia, myelodysplasia, and multiple myeloma diagnoses in patients in Ukraine, 1987-1998. Int J Hematol 2002; 76:55-60. [PMID: 12138896 DOI: 10.1007/bf02982719] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
In preparation for a possible large epidemiological study of radiation-related leukemia in Chernobyl clean-up workers of Ukraine, histologic evaluation of 62 cases of leukemia and related disorders was conducted by a panel of expert hematologists and hematopathologists from the United States, France, and Ukraine. All cases were randomly selected from a surrogate population of men in the general population of 6 regions of Ukraine who were between the ages of 20 and 60 years in 1986 and were reported to have developed leukemia, myelodysplasia, or multiple myeloma between the years 1987 and 1998. The hematologists and hematopathologists on the panel were in agreement with one another and with the previously reported diagnoses and classifications of about 90% of the cases of acute and chronic leukemia in the study. These results suggest that strong reliance can be placed on the clinical diagnoses of acute and chronic forms of leukemia and multiple myeloma that have occurred in Ukrainian Chernobyl clean-up workers providing that the diagnoses are supported by records of the patients having had adequate histologic bone marrow studies. The number of cases in this study with the diagnosis of myelodysplasia, however, was too small to draw firm conclusions.
Collapse
Affiliation(s)
- Irina Dyagil
- Research Center for Radiation Medicine, Kiev, Ukraine
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Eurelings M, Notermans NC, Van de Donk NW, Lokhorst HM. Risk factors for hematological malignancy in polyneuropathy associated with monoclonal gammopathy. Muscle Nerve 2001; 24:1295-302. [PMID: 11562908 DOI: 10.1002/mus.1147] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Polyneuropathy associated with monoclonal gammopathy of undetermined significance (MGUS) is a well-known disease entity. Of the patients with monoclonal gammopathy without neuropathy, 25% develop a hematological malignancy during long-term follow-up. Whether the frequency of hematological malignancy is similar in patients with polyneuropathy associated with monoclonal gammopathy and whether hematological screening is necessary in these patients is unknown. To determine the frequency of and risk factors for a hematological malignancy, we investigated 104 patients with polyneuropathy and monoclonal gammopathy. Potential diagnostic variables were obtained from medical history, physical and neurological examination, and laboratory analysis. The associations between potential diagnostic variables and outcome, hematological malignancy, were evaluated by univariable and multivariable logistic-regression analysis. Among our patients, 23 had a hematological malignancy (8 multiple myeloma, 10 low-grade lymphoma, 3 plasmacytoma, 1 Castleman's disease and 1 POEMS syndrome [polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes]). Weight loss, progression of the neuropathy, and an M-protein level > 1 g/L were independent risk factors for malignancy. Extensive screening is indicated in patients with these features.
Collapse
Affiliation(s)
- M Eurelings
- Department of Neurology, University Medical Center Utrecht, G03.228, P.O. Box 85500, 3508 GA Utrecht, The Netherlands.
| | | | | | | |
Collapse
|
14
|
Fernandez LA, Couban S, Sy R, Miller R. An unusual presentation of extramedullary plasmacytoma occurring sequentially in the testis, subcutaneous tissue, and heart. Am J Hematol 2001; 67:194-6. [PMID: 11391718 DOI: 10.1002/ajh.1106] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Extramedullary plasmacytoma (EMP) is a rare neoplasm of soft tissue that usually arises in the respiratory tract, nasal cavity, sinuses, and nasopharynx. It is even more uncommon for it to arise either in the testis or heart. We report the presentation of a case where plasmacytomas were found sequentially in the testis, subcutaneous tissue, and heart. EMP usually has a good prognosis except when it involves the heart. Our patient survived for only 15 months post autologous hematopoietic stem cell transplantation.
Collapse
Affiliation(s)
- L A Fernandez
- Department of Medicine, Dalhousie University and Queen Elizabeth II Health Sciences Centre, Nova Scotia, Canada.
| | | | | | | |
Collapse
|
15
|
Abstract
An extramedullary plasmacytoma was found in a 10-year-old sheep. The tumor involved the mediastinum, where a 25 x 15 x 10-cm encapsulated mass was found. The lungs had multiple metastases ranging from 0.5 to 2 cm in diameter, and the portal vein contained a 10-cm-long mass. The cytologic and histopathologic analyses were consistent with a moderately differentiated plasmacytoma. The immunophenotype of the tumor cells was lambda light chain IgG+, CD79a-, and CD3-. Occasional granulomas were observed at the periphery of the mediastinal and pulmonary tumors. Microbiologic culture yielded growth of Corynebacterium from these granulomas. This is the first report of plasmacytoma in sheep. The tumor most likely arose from mediastinal lymph nodes and metastasized to the lungs and portal vein.
Collapse
Affiliation(s)
- J Pérez
- Departamento de Anatomía y Anatomía Patológica Comparadas, Universitario de Rabanales, Ctra. Madrid-Cádiz, Córdoba, Spain.
| | | | | | | |
Collapse
|
16
|
Ong F, Hermans J, Noordijk EM, Schaar CG, Kluin-Nelemans JC. The classification of plasma cell dyscrasias: alternatives to the Durie & Salmon diagnostic system. Leuk Lymphoma 1999; 34:203-6. [PMID: 10350352 DOI: 10.3109/10428199909083400] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
17
|
Ong F, Hermans J, Noordijk EM, De Kieviet W, Seelen PJ, Wijermans PW, Kluin-Nelemans JC. Development of a "Myeloma Risk Score" using a population-based registry on paraproteinemia and myeloma. Leuk Lymphoma 1997; 27:495-501. [PMID: 9477131 DOI: 10.3109/10428199709058316] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Diagnostic systems for monoclonal gammopathies use bone marrow and X-ray examinations to exclude multiple myeloma (MM). Data from a population-based registry of unselected patients with paraproteinemia indicate that these tests are often done only when MM is suspected. We used 441 randomly selected patients to develop a simple four point "Myeloma Risk Score" based on two readily available laboratory tests. One point was given for paraprotein concentration > or = 10 g/l, one point for IgG and IgA, and two points for IgD and light chains only. A score of 0 or 1 indicated a low risk for MM, with scores of 2 and 3 signifying high risks. Sensitivity, specificity, positive and negative predictive value (PV) for the Myeloma Risk Score in the training sample were 92%, 88%, 79%, and 96% respectively. Extrapolating these results to a larger cohort showed that 90% of patients with a monoclonal gammopathy could be classified correctly as having MM or a non-myeloma condition. The Myeloma Risk Score can identify patients with a paraproteinemia at risk for MM, and who are therefore candidates for bone marrow and X-ray examination.
Collapse
Affiliation(s)
- F Ong
- Comprehensive Cancer Centre West, Leiden, The Netherlands
| | | | | | | | | | | | | |
Collapse
|
18
|
Abstract
Abstract
Multiple myeloma (MM) has an incidence of approximately four per 100,000 per year. Ninety-nine percent of patients with MM have a monoclonal (M-) protein in the serum or urine during the course of their disease. MM must be differentiated from smoldering multiple myeloma (SMM), which has an M-protein value of more than 30 g/l and more than 10% plasma cells in the bone marrow, but no other features of MM. The plasma cell labeling index (PCLI) and the presence of circulating plasma cells in the peripheral blood help to differentiate monoclonal gammopathy of undetermined significance and SMM from MM. The current median duration of survival with chemotherapy is about three years. Patients with low PCLI and low β2-microglobulin values have a median duration of survival of approximately six years. Melphalan and prednisone produce an objective response in 50% to 60% of patients. Combinations of chemotherapy produce a higher response rate, but the survival rate is not different. Allogeneic bone marrow transplantation is associated with a mortality rate of 25% within six months and an actuarial survival rate of 28% at seven years. Autologous peripheral stem cell transplantation is applicable to more patients and is reported to produce a higher response rate and longer survival than chemotherapy, but most patients will eventually have relapse.
Collapse
|
19
|
Herrinton LJ. The epidemiology of monoclonal gammopathy of unknown significance: a review. Curr Top Microbiol Immunol 1996; 210:389-95. [PMID: 8565582 DOI: 10.1007/978-3-642-85226-8_42] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Affiliation(s)
- L J Herrinton
- Division of Research, Kaiser Permanente, Oakland, CA 94611, USA
| |
Collapse
|
20
|
Ong F, Hermans J, Noordijk EM, Wijermans PW, Kluin-Nelemans JC. Presenting signs and symptoms in multiple myeloma: high percentages of stage III among patients without apparent myeloma-associated symptoms. Ann Hematol 1995; 70:149-52. [PMID: 7718643 DOI: 10.1007/bf01682035] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
We studied the medical histories of 127 patients diagnosed with multiple myeloma included in a population-based registry of 945 patients with a para-protein or multiple myeloma in the region of the Comprehensive Cancer Center West (CCCW). We defined patients "not immediately diagnosed" or "delayed diagnosis" as those patients in whom myeloma was not included in the initial differential diagnosis. We found that 37% belonged to this category. These patients more often had symptoms not associated with multiple myeloma. Since a surprising 51% of patients with delayed diagnosis turned out to have stage-III myeloma, the physician should be alert to the presence of this disease, despite the fact that co-morbidity may mask its presence.
Collapse
Affiliation(s)
- F Ong
- Comprehensive Cancer Center West, Leiden, The Netherlands
| | | | | | | | | |
Collapse
|
21
|
Ong F, Hermans J, Noordijk EM, Kluin-Nelemans JC. Is the Durie and Salmon diagnostic classification system for plasma cell dyscrasias still the best choice? Application of three classification systems to a large population-based registry of paraproteinemia and multiple myeloma. Ann Hematol 1995; 70:19-24. [PMID: 7827202 DOI: 10.1007/bf01715377] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
There are a number of systems for diagnosing multiple myeloma, myeloma variants and monoclonal gammopathy of undetermined significance. We compared three systems, those according to Durie and Salmon, to Kyle and Greipp, and to the British Columbia Cancer Agency, using material from a population-based registry of 847 patients with a paraproteinemia or multiple myeloma. Of these, 157 underwent both bone marrow and X-ray examinations and were subsequently included in our analysis. The differences between the systems were small, even though in only 64% of the cases the diagnosis according to all three systems was identical. The system used by the British Columbia Cancer Agency turned out to be the shortest and easiest system reviewed here. We propose a more frequent application of this system instead of the more commonly used Durie and Salmon and Kyle and Greipp criteria.
Collapse
Affiliation(s)
- F Ong
- Comprehensive Cancer Center West, Leiden, The Netherlands
| | | | | | | |
Collapse
|
22
|
Abstract
Tumours with a plasmacytoid pattern taken from 32 dogs and four cats were examined for the presence of immunoglobulins, which would allow them to be designated as B-cell lymphomas. Within a total of 19 immunoglobulin-positive tumours, three types could be distinguished: extramedullary plasmacytoma (15), multiple myeloma (two) and immunocytoma (two). These tumours occurred in 18 of the dogs, and in one cat (extramedullary plasmacytoma). The characteristics of the immunoglobulin-producing tumours were investigated by light and electron-microscopy as well as by immunohistochemical methods. Seventeen of the 19 tumours expressed lambda-type light chains and one tumour kappa-type light chains. Heavy chains were also synthesized by five tumours.
Collapse
MESH Headings
- Animals
- Cat Diseases/metabolism
- Cat Diseases/pathology
- Cats
- Dog Diseases/metabolism
- Dog Diseases/pathology
- Dogs
- Immunoglobulin A/analysis
- Immunoglobulin A/metabolism
- Immunoglobulin G/analysis
- Immunoglobulin G/metabolism
- Immunoglobulin M/analysis
- Immunoglobulin M/metabolism
- Immunoglobulin kappa-Chains/analysis
- Immunoglobulin kappa-Chains/metabolism
- Immunoglobulins/analysis
- Immunoglobulins/metabolism
- Immunohistochemistry
- Leukemia, Lymphocytic, Chronic, B-Cell/chemistry
- Leukemia, Lymphocytic, Chronic, B-Cell/metabolism
- Leukemia, Lymphocytic, Chronic, B-Cell/veterinary
- Lymphoma, B-Cell/chemistry
- Lymphoma, B-Cell/metabolism
- Lymphoma, B-Cell/veterinary
- Microscopy, Electron
- Multiple Myeloma/metabolism
- Multiple Myeloma/veterinary
Collapse
Affiliation(s)
- W Breuer
- Institute of Veterinary Pathology, University of Munich, F.R.G
| | | | | | | |
Collapse
|
23
|
Edwards DF, Parker JW, Wilkinson JE, Helman RG. Plasma cell myeloma in the horse. A case report and literature review. J Vet Intern Med 1993; 7:169-76. [PMID: 8331611 DOI: 10.1111/j.1939-1676.1993.tb03182.x] [Citation(s) in RCA: 49] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023] Open
Abstract
Plasma cell myelomas in horses have been reported infrequently. Data from 10 cases, 9 from the literature and 1 new case, are used to characterize the disease in the horse. Hot-blooded horses (7/10), specifically Quarter Horses (4/10), were most often affected. Median age at diagnosis was 11 years (range, 3 mo-22 yr) and both male (5) and female horses (5) were represented equally. Clinical findings included weight loss (6/8), anorexia (4/8), fever (4/8), limb edema (4/8), pneumonia (3/8), rear leg paresis/ataxia (3/8), epistaxis (3/8), palpable lymphadenopathy (2/8), and bone pain (2/8). Anemia (8/8) was present routinely, and in three horses, RBCs were macrocytic. Leukopenia (2/8), thrombocytopenia (2/8), and circulating plasma cells (3/8) were variable findings. Except for abnormal protein concentrations and hyponatremia (3), abnormal results from serum biochemical analysis including hypocholesterolemia (1), hypercalcemia (1), and azotemia (1) were reported infrequently. Hyperproteinemia (8/9), hypoalbuminemia (7/9), and hyperglobulinemia (8/9) were characteristic but not invariable findings. Monoclonal proteins (7/7) were detected in the alpha 2, beta, or gamma region by serum electrophoresis. The paraprotein's heavy chain, determined in four horses, was a subclass of IgG. Three horses had decreased concentrations of normal immunoglobulins. Variable proteinuria (trace to 4+) was detected by routine urinalysis in four of six horses. Bence Jones proteinuria was detected in one of five horses (heat precipitation) and monoclonal proteins were detected in two of three electrophoresed urine samples. Three of the horses had lytic bone lesions detected radiographically. Bone marrow aspirates were diagnostic in two of five horses.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
|
24
|
|
25
|
Abstract
When a patient presents with monoclonal gammopathy, a wide variety of clinical conditions must be considered. The importance of distinguishing accurately between patients with stable monoclonal gammopathies and those with overt multiple myeloma cannot be over-emphasised. The bone marrow examination with plasma cell labeling index, and newer techniques such as magnetic resonance imaging and computed tomography can improve diagnostic discrimination. In difficult cases, the detection of small numbers of circulating myeloma cells, the peripheral blood B-cell labeling index, and light chain isotype suppression may bring better diagnostic resolution. These tests may also be used to help assess disease activity. If the diagnosis is multiple myeloma, prediction of outcome assumes clinical importance. There are widely disparate survivals among patients with different clinical presentations. Standard clinical assays or a combination of these as in clinical staging do not provide sufficient prediction of outcome but are routinely available and therefore widely used. Independent predictive tests such as the plasma cell labeling index and beta 2-microglobulin improve prognostic accuracy. Ploidy analysis and immunophenotyping are additional variables that may assume more importance as the results of ongoing studies appear. Other promising approaches include detection of oncogene and multiple drug resistance gene expression. All such techniques will become more relevant as we apply more intensive treatment earlier in the disease course, particularly for the younger myeloma patients in whom the prognosis is poor.
Collapse
Affiliation(s)
- P R Greipp
- Division of Hematology and Internal Medicine, Mayo Clinic, Rochester MN 55905
| |
Collapse
|
26
|
Bourne WM, Kyle RA, Brubaker RF, Greipp PR. Incidence of corneal crystals in the monoclonal gammopathies. Am J Ophthalmol 1989; 107:192-3. [PMID: 2913816 DOI: 10.1016/0002-9394(89)90225-0] [Citation(s) in RCA: 29] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Affiliation(s)
- W M Bourne
- Department of Ophthalmology, Mayo Clinic and Foundation, Rochester, MN 55905
| | | | | | | |
Collapse
|